Mylan N.V. (MYL): $1.45 million was the positive money flow into the stock on Monday and the up/down ratio of ticks was also in favor of the bulls at 6.54. The value of trades done on upticks was $1.71 million, whereas, trades done on downticks were valued at $0.26 million. Money flows are calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades. large traders, also sometimes called as the smart money, block traded $1.43 million worth stocks on upticks, which is a bullish indication. The money flow in block trades was $1.43 million. Mylan N.V. (MYL) fell $0.01 traded at $45.44, a change of -0.02% over the previous day. The stock is 2.02% for the week.
Mylan N.V. has dropped 4.35% during the last 3-month period . Year-to-Date the stock performance stands at -15.79%. Shares of Mylan N.V. rose by 2.2% in the last five trading days and 1.07% for the last 4 weeks. In a related news, The Securities and Exchange Commission has divulged in a Form 4 filing that the director of Mylan N.V., Maroon Joseph C Md had purchased shares worth of $75,067 in a transaction dated on June 3, 2016. A total of 1,670 shares were purchased at a price of $44.95 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
Mylan N.V. (NASDAQ:MYL): stock turned positive on Monday. Though the stock opened at $45.56, the bulls momentum made the stock top out at $45.92 level for the day. The stock recorded a low of $45.41 and closed the trading day at $45.53, in the green by 0.18%. The total traded volume for the day was 3,529,839. The stock had closed at $45.45 in the previous days trading.
Mylan N.V., formerly Mylan Inc., is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty. The Companys generic pharmaceutical business is conducted primarily in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA); and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its specialty pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). The Companys API business is conducted through Mylan Laboratories Limited (Mylan India), which is included within the Asia Pacific region in its Generics Segment. Mylan provides products to customers in approximately 140 countries and territories.